Intellia Therapeutics
Chris Argento is currently the Senior Process Development Engineer at Intellia Therapeutics, Inc. Chris previously worked at Biogen as an Engineer III, Engineer II, and Engineer I in Downstream Process Development for Gene Therapy PD. Chris also has experience as a Fluidics Intern at imec, a Purification Development Intern at Genentech, and a Nanotechnology Research Assistant at Johns Hopkins University. Chris holds a Master of Science in Engineering in Chemical and Biomolecular Engineering, as well as a Bachelor of Science in Chemical & Biomolecular Engineering from The Johns Hopkins University. Chris was the Valedictorian of Miller Place High School.
Intellia Therapeutics
9 followers
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.